Last month, the company said it was planning a $7.5 million public offering of 6.25 million shares and warrants for another 6.25 million shares.
The company also entered into two separate financing agreements totaling $41.5 million with Innovatus Life Sciences Lending Fund, East West Bank, and Aspire Capital.
The institute — part of the European Molecular Biology Laboratory — said it will use the new funding to increase its computing, storage, and building capacity.
Clinical informatics startup Ovation looks to grow its business in laboratory information systems for precision molecular diagnostic labs.
The biotech startup, which had been working with Cas12 and Cas13, has now licensed the recently discovered Cas14 protein from UC Berkeley.
The in vitro diagnostic uses next-generation sequencing to detect clinically actionable genetic variants to guide therapy selection for cancer patients.
Palmetto's MolDx has agreed to cover Myriad's MyPath Melanoma to help rule out the disease when the biopsy can't be definitively classified by standard clinical and histopathological characteristics.
Under deal, HTG will sell to or through Cowen from time to time $40 million of its common stock though it is not obligated to sell any shares.
A statement from NIH Director Francis Collins follows a call by scientists for the moratorium pending the creation of a framework to guide the use of heritable genome editing.
The company will launch a clinical version of its liquid biopsy assay in the second quarter and plans to launch clinical trials that make the case for reimbursement.
The company — a spinout of the New York Genome Center — said it will use the funding in part to develop its technologies for new applications in agriculture.
Epigenomics terminated a licensing contract related to Chinese distribution rights for its Septin9 biomarker and Epi proColon colorectal cancer blood test.
The company said it intends to use the proceeds of the placement to continue work on its microfluidic PCR-based platform for pathogen detection.
The company ran 668,600 tests during the year, a 30 percent increase from its 2017 testing volume.
The firm said revenues from its precision oncology business increased 98 percent in Q4, driven by higher testing volume and increased revenue per test.
The deal will focus on Biocartis' Idylla MSI test, which provides information on a tumor's microsatellite instability status of a tumor from a single FFPE slice.
The company said that diagnostic testing volumes, product and royalty revenues, and clinical services revenues all fell year over year.
The budget calls for $34.4 billion for the NIH in the coming fiscal year, including $492 million in resources made available through the 21st Century Cures Act.
The agency said it is sensitive to stakeholder concerns and is working with MACs to adjust claims processing systems.
Shanghai RAAS will become Grifols' exclusive distributor of plasma-derived products and transfusion diagnostic solutions in China.
Two researchers are calling for education for scientists on defending facts.
Researchers were among those who marched in London this weekend to call for another vote on Brexit.
Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant.
In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.